CEACAM5 Overexpression

This path is for exploring information that is relevant to patients who have shown the KRAS-G12C mutation

“CEACAM5 is a cell surface glycoprotein that is not highly expressed in several normal tissues, including colon, esophagus, and head and neck. However, the protein is often highly expressed in a few tumor types, such as gastrointestinal, breast, and lung. Approximately 20% of patients with NSCLC exhibit overexpression of CEACAM5.” – Onclive

The CEACAM5 target is currently being studied by Sanofi using “Tusamitamab Ravtansine”